surrogate endpoint

Related by string. surrogate endpoints * surrogates . Surrogates . SURROGATES . SURROGATE . Surrogate : surrogate mothers . surrogate markers . Broderick surrogate . surrogate mother . surrogate campaigners / Endpoints . EndPoint . Endpoint . endpoints : primary efficacy endpoint . Secondary endpoints include . secondary efficacy endpoints . video conferencing endpoints . Secondary endpoints included * *

Related by context. All words. (Click for frequent words.) 70 follicular NHL 68 KRAS status 67 recurrent glioblastoma multiforme 67 azacitidine 67 tocilizumab 66 dasatinib 66 Gefitinib 66 antiangiogenic therapy 66 QTc prolongation 66 riociguat 66 mycophenolate mofetil 66 xanthine oxidase inhibitor 66 decitabine 66 APTIVUS r 65 prospectively defined 65 bendamustine 65 neoadjuvant chemotherapy 65 MGd 65 eplerenone 65 antithrombotic 65 viral kinetics 65 oral anticoagulation 65 OPAXIO 65 Dasatinib 65 clinical endpoints 65 Vidaza azacitidine 65 VAPRISOL 65 noninferiority 65 MAGE A3 ASCI 64 Xanafide 64 sipuleucel T 64 Doxil ® 64 GP IIb IIIa inhibitors 64 tumor histology 64 antithrombotic therapy 64 trabectedin 64 temsirolimus 64 VIDAZA 64 mRCC 64 calcineurin inhibitors 64 pharmacodynamic PD 64 vidofludimus 64 monotherapy 64 pertuzumab 64 β blockers 64 Amrubicin 64 NAbs 64 fondaparinux 64 PREZISTA r 64 sorafenib Nexavar 64 sirolimus eluting stents 64 Octreolin 64 canakinumab 64 doxorubicin docetaxel 64 Riluzole 64 platelet reactivity 64 anti androgen 64 antihypertensive agents 63 chemoradiotherapy 63 oral anticoagulant 63 azacytidine 63 Mylotarg 63 sunitinib 63 ATACAND 63 Diovan HCT 63 anti leukemic 63 FOLFIRI 63 rFVIIa 63 surrogate markers 63 5-FU/LV 63 infusional 5-FU/LV 63 galiximab 63 RECIST Response Evaluation Criteria 63 docetaxel chemotherapy 63 sustained virological response 63 thalidomide Thalomid 63 LMWH 63 Fludara 63 DFMO 63 thrombolytic agents 63 standard chemotherapy regimen 63 non metastatic osteosarcoma 63 MabCampath 63 rtPA 63 vandetanib 63 prognostic variables 63 CLORETAZINE TM VNP#M 63 teriflunomide 63 liposomal doxorubicin 63 erlotinib Tarceva 63 pharmacokinetic PK 63 therapeutic regimens 63 AZILECT R 63 bortezomib Velcade 63 fluoropyrimidine 63 idraparinux 63 vorinostat 63 Secondary endpoints include 63 Azedra 63 Kaplan Meier analysis 63 cilostazol 63 Response Evaluation Criteria 63 lapatinib Tykerb 63 glatiramer acetate 63 antihypertensive therapy 62 Temsirolimus 62 TNF inhibitor 62 antiplatelet therapies 62 Cytoxan 62 tipranavir 62 antiplatelet drugs 62 cardiac toxicity 62 ZOLINZA 62 abacavir lamivudine 62 CoFactor 62 irbesartan 62 chemotherapeutic regimen 62 ACTEMRA TM 62 IRESSA 62 Lenalidomide 62 PROCHYMAL 62 RECIST criteria 62 Erlotinib 62 talabostat 62 EFAPROXYN 62 pomalidomide 62 antiplatelet agent 62 sustained virologic response 62 surrogate marker 62 pain palliation 62 immunosuppressive regimen 62 tecarfarin 62 APTIVUS 62 pharmacodynamic 62 elotuzumab 62 renal toxicity 62 YERVOY 62 calcineurin inhibitor 62 sirolimus 62 ixabepilone 62 neratinib 62 immunosuppressive agents 62 Taxotere ® 62 platelet inhibitor 62 mecamylamine 62 antiarrhythmic drug 62 EGFR TKI 62 trastuzumab Herceptin ® 62 cangrelor 62 GAMMAGARD 62 vismodegib 62 prognostic indicator 62 ELACYT 62 ARB telmisartan 62 fulvestrant 62 ispinesib administered 62 clinically meaningful differences 62 interferon alfa 62 nonrandomized 62 AZILECT 62 chemotherapeutic agent 62 oral FTY# 62 PCA3 assay 62 Combination therapy 62 efficacy endpoint 62 gemcitabine carboplatin 62 Hydroxyurea 62 topical calcineurin inhibitors 62 paclitaxel eluting stents 62 cabazitaxel 62 ADAGIO study 62 alteplase 62 adjuvant therapy 62 composite endpoint 62 #mg dose [003] 62 Targretin capsules 62 virological response 62 Targretin 62 Bortezomib 62 alefacept 62 antiplatelet therapy 62 gadobutrol 62 recurrent GBM 62 pemetrexed 62 tanespimycin 62 symptomatic VTE 62 Bevacizumab 62 Onrigin 62 fluvastatin 62 thromboembolic events 62 virologic responses 62 erlotinib Tarceva ® 62 Gliadel Wafer 62 unfractionated heparin 62 EBMT criteria 62 glufosfamide 62 CIMZIA ™ 62 antiangiogenic agent 62 angiotensin converting enzyme inhibitors 62 cetuximab 62 CANCIDAS 61 DACH platinum 61 Telintra 61 SERMs 61 Natalizumab 61 PROMACTA 61 locoregional 61 bevacizumab Avastin ® 61 Velcade bortezomib 61 octreotide LAR 61 thienopyridine 61 aldosterone antagonists 61 prognostic indicators 61 amphotericin B 61 preoperative chemotherapy 61 serum urate 61 Pemetrexed 61 antiangiogenic agents 61 pCR 61 liver metastasis 61 Cetuximab 61 otamixaban 61 strontium ranelate 61 CYP#A# inhibitors 61 differentiated thyroid 61 assessing T DM1 61 DOXIL 61 pegfilgrastim 61 neoadjuvant therapy 61 refractory rituximab naive 61 ULORIC 61 TAXUS Stent 61 ToGA 61 Secondary endpoints 61 Sorafenib 61 NOXAFIL 61 IFN beta 61 myocardial reperfusion 61 fibrinolytic 61 RoACTEMRA 61 nephrotoxicity 61 vinorelbine 61 DMARD 61 T#I [002] 61 docetaxel Taxotere 61 KRAS mutation 61 GnRH agonists 61 chlorambucil 61 erythropoietic 61 Perforomist ™ Inhalation Solution 61 cediranib 61 Tekamlo 61 desvenlafaxine succinate 61 peginterferon alfa 61 CIMZIA TM 61 COREG 61 superficial bladder cancer 61 bicalutamide 61 gefitinib Iressa 61 prespecified 61 varespladib 61 receptor tyrosine kinase inhibitor 61 Vidofludimus 61 AChE inhibitors 61 INTELENCE 61 mCRC patients 61 abatacept 61 boosted protease inhibitor 61 endoscopic gastric ulcers 61 Xinlay 61 protease inhibitor PI 61 clinicopathological features 61 abiraterone acetate 61 ponatinib 61 gefitinib 61 peptide BNP 61 tacrolimus ointment 61 Xelox 61 pegylated liposomal doxorubicin 61 tumor lysis syndrome 61 ICD therapy 61 biologic therapy 61 antioxidant supplementation 61 topotecan 61 antithrombotics 61 nab paclitaxel 61 plus dexamethasone 61 secondary endpoint 61 Zevalin consolidation 61 Tamibarotene 61 leflunomide 61 bevacizumab 61 dacarbazine chemotherapy 61 Abatacept 61 rosuvastatin #mg 61 glycated hemoglobin levels 61 pharmacodynamic parameters 61 ACE inhibitor ramipril 61 paclitaxel Taxol 61 mTOR inhibitors 61 FASLODEX 61 FOLFOX4 61 tenofovir DF 61 nilotinib 61 icatibant 61 macrolide antibiotic 61 crizotinib PF # 61 Primary endpoints 61 salmeterol fluticasone 61 anti arrhythmic 61 clodronate 61 bevacizumab Avastin 61 pharmacodynamic effects 61 paricalcitol 61 5 Fluorouracil 61 anticoagulant warfarin 61 APPRAISE 61 achieve sustained virologic 61 pharmacokinetic interactions 61 hydroxychloroquine 61 valsartan 61 denileukin diftitox 61 lipid lowering drugs 61 TEMODAL 61 Faslodex 61 dose dexamethasone 61 Traficet EN 61 TroVax ® 61 metastatic renal cell carcinoma 61 ELOXATIN 61 alkylating agent 61 dexamethasone Decadron 61 colorectal liver metastases 61 enzastaurin 61 TNFerade 61 peginterferon 61 antiarrhythmic drugs 61 plasma pharmacokinetics 60 active comparator 60 cinacalcet 60 pazopanib 60 anti angiogenic agents 60 dacarbazine 60 BENICAR HCT 60 chemosensitivity 60 VerifyNow 60 mg kg dose 60 pharmacodynamic endpoints 60 somatostatin analogues 60 DMARDS 60 Allovectin 7 ® 60 ganetespib 60 Removab 60 mesalamine granules 60 Noxafil 60 estramustine 60 antitumor effect 60 CCyR 60 INVEGA ® 60 aspirin clopidogrel 60 neurologic progression 60 docetaxel Taxotere ® 60 interferon therapy 60 APTIVUS R 60 progression TTP 60 immunomodulator 60 cardiovascular morbidity 60 antidiabetic drugs 60 CA4P 60 surrogate endpoints 60 peg interferon 60 tolerability profiles 60 Rasagiline 60 COPAXONE R 60 Solid Tumors criteria 60 secondary efficacy endpoints 60 microtubule inhibitor 60 pharmacodynamic properties 60 Torisel 60 metastatic HRPC 60 Mitoxantrone 60 Nexavar sorafenib 60 chemotherapeutic drug 60 KRAS mutation status 60 GnRH agonist 60 lumiliximab 60 inhaled iloprost 60 Laquinimod 60 Vimpat R 60 atherothrombotic events 60 mapatumumab 60 RAPAFLO 60 HSCT 60 hemostatic efficacy 60 factor Xa inhibitor 60 HER2 overexpression 60 interferon alfa 2b 60 fosbretabulin 60 eTag assays 60 TNF alpha inhibitor 60 eptifibatide 60 adenoma recurrence 60 relapsed MCL 60 Candesartan 60 adverse cytogenetics 60 REMINYL ® 60 resectable 60 intravenous cyclophosphamide 60 Fingolimod 60 vernakalant hydrochloride 60 eltrombopag 60 AST ALT 60 thrombolytic therapy 60 rHuEPO 60 Adalimumab 60 non selective NSAIDs 60 angiographic outcomes 60 sorafenib tablets 60 mitoxantrone 60 favorable pharmacokinetic profile 60 rilonacept 60 pegylated interferon alfa 2b 60 TACE 60 anti angiogenic drugs 60 RSD# 60 imatinib therapy 60 paliperidone palmitate 60 pharmacokinetic characteristics 60 taxane therapy 60 glomerular filtration 60 xenograft models 60 caspofungin 60 MICARDIS ® 60 histological subtype 60 arbaclofen 60 fibrinolytic therapy 60 tolvaptan 60 dose clopidogrel 60 tipranavir r 60 DMARDs 60 trastuzumab Herceptin 60 relapsing multiple sclerosis 60 TYKERB 60 Pharmacokinetic 60 clomipramine 60 follicular lymphoma FL 60 Abacavir 60 palifosfamide 60 vemurafenib 60 Carvedilol 60 lenalidomide 60 olmesartan 60 BAY #-# 60 Ranolazine 60 VerifyNow P#Y# Test 60 mycophenolic acid 60 Aclidinium 60 uric acid lowering 60 eszopiclone 60 EOquin TM 60 genotypic resistance 60 Tavocept 60 multivariate Cox 60 β blocker 60 OHR/AVR# 60 HuMax EGFr 60 levosimendan 60 systemic corticosteroids 60 haematologic 60 FAMPYRA 60 infliximab Remicade 60 imatinib 60 ACCORD Lipid 60 CIMZIA TM certolizumab pegol 60 PNH patients 60 prostate cancer PCa 60 antihypertensive medications 60 GSK# [001] 60 visilizumab 60 SCIg 60 viral kinetic 60 lacosamide 60 predictive biomarker 60 VKORC1 60 concomitant medications 60 peginterferon alfa 2b 60 octreotide 60 etravirine 60 Onrigin TM 60 dasatinib Sprycel 60 imatinib Gleevec 60 anti TNF 60 inotropic 60 oxcarbazepine 60 dosage regimens 60 gemcitabine 60 SCH # 60 Gemzar ® 60 antiepileptic drug 60 TTF Therapy 60 complete cytogenetic response 60 oral prodrug 60 Specifid 60 BRAF inhibitor 60 ticagrelor 60 antihypertensive drugs 60 Degarelix 60 aflibercept 60 primidone 60 CCX# 60 pyridostigmine 60 TORISEL 60 CINTREDEKIN BESUDOTOX 60 PEG IFN 60 BARACLUDE ® 60 administered subcutaneously 60 zoledronic acid 60 nucleoside analog 60 custirsen 60 ACZ# 60 edifoligide 60 clevidipine 60 factor Xa 60 fosamprenavir 60 eribulin mesylate 60 ziprasidone 60 Arranon 60 FOLFOX 60 melphalan prednisone 60 thrombus aspiration 60 ximelagatran 60 Dendreon Provenge 60 Tolvaptan 60 lanthanum carbonate 60 Trastuzumab 60 IV bisphosphonates 60 ADCS CGIC 60 Onconase 60 ICD shocks 60 secondary efficacy endpoint 60 sulphonylureas 60 Tarceva TM 60 FDG PET 60 direct thrombin inhibitors 60 nonclinical studies 59 intravenous bisphosphonates 59 MYDICAR 59 carvedilol 59 MyVax 59 lenalidomide Revlimid R 59 CsA 59 mcg dose 59 intracoronary 59 YONDELIS 59 HER2 expression 59 reinfarction 59 Decitabine 59 IFN α 59 ARIXTRA 59 biodistribution 59 heavily pretreated 59 HoFH 59 Vidaza ® 59 MYLOTARG 59 Taxol ® 59 TAXUS Express Stent 59 clopidogrel Plavix 59 Aptivus ® 59 relapsed MM 59 antiepileptics 59 response CCyR 59 immunosuppressant drug 59 ARCOXIA 59 ABC/3TC 59 Telmisartan 59 postoperative chemotherapy 59 IMGN# 59 thrombolytics 59 Dapagliflozin 59 fallopian tube cancers 59 mTOR inhibitor 59 synthetic retinoid 59 Azacitidine 59 pharmacokinetic PK profile 59 forodesine 59 neoadjuvant 59 intermittent dosing 59 XELOX 59 perampanel 59 CBLC# 59 PSA nadir 59 allogeneic HSCT 59 QTc 59 HER2 positive metastatic breast 59 TNF antagonist 59 tenofovir emtricitabine 59 pioglitazone 59 lamotrigine 59 nomograms 59 Corticosteroids 59 entecavir 59 EDEMA3 trial 59 EGFR antibodies 59 androgen deprivation 59 upper gastrointestinal bleeding 59 DAPT 59 ADVEXIN 59 BENICAR 59 DU #b 59 oral rivaroxaban 59 Oncotype DX Recurrence Score 59 vasopressor 59 endometrial hyperplasia 59 ZYVOX 59 goserelin 59 paliperidone ER 59 Vectibix monotherapy 59 antiarrhythmic 59 Neurodex 59 Zolinza 59 bortezomib 59 divalproex sodium 59 ritonavir boosted 59 #mg/day [001] 59 HAART regimens 59 anti arrhythmic drug 59 clinically meaningful 59 efaproxiral 59 CHARM Added 59 Gleevec resistant 59 Deforolimus 59 anticancer treatments 59 ZD# [001] 59 certolizumab 59 antimicrobial prophylaxis 59 Treanda 59 BEXXAR Therapeutic Regimen 59 Cimzia TM 59 cetuximab Erbitux 59 samalizumab 59 anakinra 59 hematologic toxicity 59 imatinib resistance 59 plasma uric acid 59 lipid lowering therapy 59 chemoradiation therapy 59 TriRima 59 bucindolol 59 Ceplene/IL-2 59 Flu Cy 59 gemcitabine Gemzar ® 59 abciximab 59 liposomal formulation 59 pulmonary exacerbations 59 tigecycline 59 Bivalirudin 59 Aliskiren 59 ACE Inhibitor 59 adalimumab 59 axitinib 59 Campath alemtuzumab 59 lenalidomide dexamethasone 59 busulfan 59 coxibs 59 evaluating tivozanib 59 transgene expression 59 EGFR tyrosine kinase inhibitors 59 alvimopan 59 IIIa inhibitor 59 pretest probability 59 LHRH agonists 59 STRIDE PD 59 ISENTRESS 59 OncoVEX 59 Fludara ® 59 EGFR expressing mCRC 59 prasugrel Effient 59 bortezomib Velcade ® 59 Non inferiority 59 antimetabolite 59 cobiprostone 59 warfarin therapy 59 NATRECOR ® 59 Adjuvant chemotherapy 59 Hematologic toxicity 59 interferon beta therapy 59 bezafibrate 59 HuMax CD4 59 prednisone prednisolone 59 NIHSS score 59 sorafenib Nexavar ® 59 VTE prophylaxis 59 Valsartan 59 CHOP chemotherapy 59 BRAF inhibitors 59 Pazopanib 59 relapsed ovarian cancer 59 metformin sulfonylurea 59 rt PA 59 Pharmacokinetics PK 59 glycosylated hemoglobin levels 59 leukotriene receptor antagonists 59 temsirolimus Torisel ® 59 lomitapide 59 Secondary endpoints included 59 efalizumab 59 plasma renin activity 59 QuadraSphere 59 latanoprost 59 KRAS mutations 59 CRp 59 bosentan 59 Gleevec imatinib 59 nicardipine 59 EndoTAGTM 1 59 cilengitide 59 PSADT 59 ginkgo extract 59 Cloretazine 59 endothelin receptor antagonists 59 bleomycin 59 Subgroup analyzes 59 Ceflatonin 59 SYNTAX trial 59 beta blocker therapy 59 CTAP# Capsules 59 oral Xeloda 59 Subgroup analysis 59 trastuzumab DM1 59 non squamous NSCLC 59 aliskiren 59 chemotherapy docetaxel 59 dobutamine 59 alkylating agents 59 efficacy tolerability 59 BYSTOLIC 59 trials RCTs 59 natalizumab 59 ADAS Cog 59 TYZEKA 59 cetuximab Erbitux ® 59 tricyclic antidepressant 59 inhaled corticosteroid therapy 59 alpha blocker 59 systemic immunosuppressive drugs 59 mepolizumab 59 lintuzumab 59 velafermin 59 mitomycin 59 overlapping toxicities 59 INC# 59 tipifarnib 59 VELCADE melphalan 59 serum phosphorous 59 Orazol 59 FOLFIRINOX 59 hypercalcemia 59 dose Iluvien 59 RISPERDAL ® 59 Tekturna HCT 59 Pioglitazone 59 Vectibix 59 Exemestane 59 Crohn Disease Activity 59 preclinical efficacy 59 iniparib 59 iroxanadine 59 aprepitant 59 febuxostat 59 ritonavir boosted lopinavir 59 proteasome inhibitor 59 regorafenib 59 INCB# [001] 59 inecalcitol 59 CTEPH 59 INTEGRILIN 59 COPAXONE ® 59 TRILIPIX 59 etanercept 59 Nesiritide 59 MADIT II 59 Pharmacokinetic parameters 59 posaconazole 59 Vaprisol 59 peginesatide 59 OncoVEX GM CSF 59 NEVO ™ 59 RE LY ® 59 subgroup analyzes 59 leukocyte count 59 prognostic marker 59 rituximab Rituxan 59 locoregional recurrence 59 insulin sensitizing 59 bivalirudin 59 antiplatelet medications 59 ADVEXIN therapy 59 sargramostim 59 ImmuKnow assay 59 Votrient 59 Arixtra 59 everolimus eluting stents 59 prognostic significance 59 tranylcypromine 59 pegylated alpha interferon 59 Bezielle 59 panitumumab Vectibix 59 Dabigatran etexilate 59 relapsed SCLC 59 streptokinase 59 titrated glipizide 59 gastrointestinal stromal tumors GIST 59 Vilazodone 59 ancrod 59 epithelial tumors 59 Teriparatide 59 Celecoxib 59 inhibitor RG# 59 Sandostatin LAR 59 endoscopic remission 59 bronchial hyperresponsiveness 59 CLARITY study 59 motesanib 59 sorafenib 59 olaparib 59 reboxetine 59 low dose ritonavir 59 antiandrogens 59 LIALDA 58 alvespimycin 58 Onbrez Breezhaler 58 ibandronate 58 Teriflunomide 58 oral prednisolone 58 aldosterone antagonist 58 Lp PLA 2 58 fluorouracil 58 bovine thrombin 58 intravenous dosing 58 virologic 58 CAELYX 58 Halaven 58 Exforge HCT 58 mutant KRAS 58 intravenous diuretics 58 Tasigna prolongs 58 intradermal injection 58 Surgical resection 58 durable remissions 58 airway responsiveness 58 ß blockers 58 #F FDG PET 58 ORENCIA R 58 aleglitazar 58 systemically administered 58 antiplatelet 58 phosphate binders 58 dose atorvastatin 58 maximally tolerated dose 58 stavudine d4T 58 MIRCERA 58 histologies 58 grade glioma 58 QVAR ® 58 SPIRIVA HandiHaler 58 TLK# 58 Elitek 58 prospectively stratified 58 cholinesterase inhibitors 58 Arsenic trioxide 58 Certican 58 ribavirin RBV 58 Fulvestrant 58 Genasense 58 OvaRex MAb 58 oral iron chelator 58 carboplatin paclitaxel 58 naproxen esomeprazole magnesium 58 histologic subtype 58 Pharmacokinetic studies 58 pentoxifylline 58 Lp PLA2 58 free survival PFS 58 deferiprone 58 cytostatic 58 oral antidiabetic 58 Unified Parkinson Disease 58 complete cytogenetic 58 Methylnaltrexone 58 thrombotic events 58 dexrazoxane 58 MyVax R 58 APOPTONE 58 pharmacodynamics PD 58 indolent NHL 58 statin cholesterol lowering 58 GFT# 58 convenient dosing regimens 58 NATRECOR R 58 plus COPEGUS 58 docetaxel 58 EXJADE 58 clinically meaningful efficacy 58 CMV reactivation 58 zalutumumab 58 amrubicin 58 Imprime PGG 58 Vandetanib 58 bortezomib Velcade R 58 Tracleer R 58 PRISTIQ 58 antiplatelet agents 58 triphendiol 58 PXD# 58 micafungin 58 figitumumab 58 UPLYSO 58 lipid lowering therapies 58 phase IIb clinical 58 rHuPH# 58 Panzem R NCD 58 VEGF inhibitors 58 low dose cytarabine 58 gemcitabine chemotherapy 58 FTY# 58 anastrozole 58 DaTscan 58 rosuvastatin 58 neostigmine 58 Resolute DES 58 PROSTVAC TM 58 Certolizumab pegol 58 EGFr 58 Vivaglobin 58 FOLPI 58 orBec 58 candesartan 58 TAXUS Liberte Stent 58 Taxotere chemotherapy 58 abiraterone 58 tirofiban 58 HES CEL 58 AGILECT R 58 Tacrolimus 58 Pralatrexate 58 HIF PH inhibitors 58 rituximab 58 LT NS# 58 paclitaxel cisplatin 58 sirolimus stent 58 TREANDA 58 indibulin 58 splenectomized patients 58 HMG CoA reductase inhibitors 58 drug eluting coronary stents 58 DexaSite 58 Chemophase 58 Victoza R 58 curative resection 58 conditional logistic regression 58 antibody titer 58 CINQUIL 58 adecatumumab 58 Vernakalant 58 NEVO TM 58 antiretroviral regimen 58 empiric 58 Femara letrozole 58 virologic failure 58 disease modifying antirheumatic 58 reslizumab 58 topiramate Topamax 58 pegylated interferon alfa 58 somatostatin analogs 58 thromboprophylaxis 58 immunosuppressive therapies 58 corticosteroid therapy 58 liposomal amphotericin B 58 Topotecan 58 oxaliplatin Eloxatin 58 plasma kallikrein inhibitor 58 tesmilifene 58 Marqibo 58 LY# [003] 58 insulin glargine 58 alpha interferon 58 cyclosporin 58 d dimer 58 MP4OX 58 G CSF 58 Interferon alfa 58 CYP#C# genotype 58 PRT# 58 leukotriene receptor antagonist 58 estimated GFR 58 achieved sustained virological 58 subcutaneously administered 58 epoetin alfa 58 Moxifloxacin

Back to home page